Venture
Cardurion Pharmaceuticals, Inc.
Latest Form D 2024-07-24- CIK 1702453
- State MA
- Biotechnology
- 5 Form D offerings since 2017-04-04
- Total sold
- $432M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2017-04-04
- Latest round
- $260M
- 2024-07-24 · 021-519629
- Investors
- 19
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2024-07-24 · $260M
- 2017-04-04$15.7M021-283999
- 2019-11-20$10M021-353793
- 2021-11-03$128M021-419648
- 2022-12-30$17.5M021-469288
- 2024-07-24$260M021-519629
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($260M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-519629 | First filed2024-07-24 | Latest2024-07-24 | Sought$260M | Sold$260M | Investors19 | Exemptions506(b) |
| 021-469288 | First filed2022-12-30 | Latest2022-12-30 | Sought$17.5M | Sold$17.5M | Investors2 | Exemptions506(b) |
| 021-419648 | First filed2021-11-03 | Latest2023-07-14 | Sought$128M | Sold$128M | Investors2 | Exemptions506(b) |
| 021-353793 | First filed2019-11-20 | Latest2019-11-20 | Sought$10M | Sold$10M | Investors2 | Exemptions506(b) |
| 021-283999 | First filed2017-04-04 | Latest2017-04-04 | Sought$22.5M | Sold$15.7M | Investors1 | Exemptions506(b) |
Who backs Cardurion Pharmaceuticals, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2024-07-24
| Name | Relationship |
|---|---|
| Peter Lawrence | RelationshipExecutive Officer, Director |
| Michael Mendelsohn | RelationshipExecutive Officer, Director |
| Jeb Keiper | RelationshipDirector |
| Nicholas Downing | RelationshipDirector |
| Evan Rachlin | RelationshipDirector |
| Adam Koppel | RelationshipDirector |
| Daniel Lynch | RelationshipDirector |
| Edward Mathers | RelationshipDirector |
| Emma Reeve | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| SVB Leerink LLC | CRD39011 | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2017-04-04
- Latest filing
- 2024-07-24
Who backs Cardurion Pharmaceuticals, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗